ClinicalTrials.gg
TerminatedNCT02638129Updated Feb 27, 2017Results posted

Naltrexone/Bupropion Cardiovascular Outcomes Study

A Phase 4 interventional study of Naltrexone HCl/Bupropion HCl ER and Placebo in Obesity and Cardiovascular Diseases, sponsored by Orexigen Therapeutics, Inc. Terminated at 139 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-27.

Sponsored by Orexigen Therapeutics, Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Enrollment
12th of 23
67 · median 67
Started
2016
with 1 other
Phase 4
6 of 23
2 open now
Registered
12th of 23
by date
Lead sponsor
10 of 23
Orexigen Therapeutics, Inc

Among the 23 studies testing naltrexone in Obesity, this one is the 12th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 4, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse cardiovascular events (MACE) when given in combination with standard of care in overweight and obese participants with documented history of CV disease.

Read the detailed description

The drug being evaluated in this study is naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB). NB is being evaluated in this study to rule out excess cardiovascular risk. This study will evaluate the occurrence of major adverse CV events in participants who take NB compared with placebo given in combination with standard of care in overweight and obese participants with documented history of CV disease.

The study will enroll approximately 8800 patients. After a 2-week lead-in period evaluating tolerance to NB (participants were randomly assigned in a 1:1 ratio to 1 week of NB [1 tablet per day] followed by 1 week of placebo [1 tablet per day] or 1 week of placebo followed by 1 week of NB), participants will be randomly assigned to one of two treatment groups in a 1:1 ratio, which will remain undisclosed to the patient, study site personnel, and investigator/study physician during the study (unless there is an urgent medical need):

  • Naltrexone HCl 8 mg/bupropion 90 mg extended release combination tablets
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

All participants will be asked to take tablet(s) in the AM and PM at the same time each day throughout the study.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 6 years. Participants will make multiple visits to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Obesity
  • Cardiovascular Diseases

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  1. Participant signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  1. Has (BMI) ≥27.0 kg/m\^2 at Screening. 4. Is male or female and aged ≥18 years at Screening. 5. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent through 12 weeks after the last dose of study medication.
  1. Participant meets at least 1 the following categories of cardiovascular (CV) disease (a-c):
  1. Documented coronary artery disease (at least 1 of the following 2 criteria must be satisfied):

    1. A documented history of myocardial infarction (MI) occurring greater than 3 months prior to Screening.
    2. History of coronary revascularization with at least 1 of the following:

      1. Coronary artery bypass graft surgery occurring greater than 3 months prior to Screening.
      2. Percutaneous coronary intervention (PCI) occurring greater than 3 months prior to Screening.
  2. Documented peripheral arterial disease (at least 1 of the following 3 criteria must be satisfied):

    1. Current intermittent claudication or verified ischemic ulcer(s) together with documented ankle-brachial index ≤0.85.
    2. History of previous vascular intervention for intermittent claudication or resting limb ischemia greater than 3 months prior to Screening (example: amputation for arterial disease, peripheral bypass, or history of angioplasty/stenting).
    3. History of symptomatic carotid artery disease (requiring revascularization with carotid endarterectomy or stenting) greater than 3 months prior to Screening or ≥50% stenosis on at least one carotid artery documented by duplex ultrasonography, magnetic resonance angiography, computed tomographic angiography, or catheter-based contrast angiography.
  3. Documented cerebrovascular disease (at least 1 of the following 2 criteria must be satisfied):

    1. A history of confirmed by a neurologist greater than 3 months prior to Screening and clinically and neurologically stable at Screening.
    2. A history of ischemic stroke (with a Modified Rankin Scale Score ≤3) greater than 3 months prior to Screening and clinically and neurologically stable at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound or investigational device within 3 months prior to Screening.
  2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  3. Has had an MI or unstable angina within 3 months of Screening.
  4. Has planned bariatric surgery, cardiac surgery, coronary revascularization, or peripheral artery revascularization.
  5. Has history of bariatric surgery (eg, Roux-en-Y gastric bypass, duodenal switch, or sleeve gastrectomy).
  6. Has had a procedure for weight loss other than bariatric surgery (eg, gastric banding or any other devices that maybe used in obesity treatment) within past 12 months prior to Screening.
  7. Has a history of or allergies to any component of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) or .
  8. Has a history of cancer that has been in remission for \<5 years prior to Screening. A history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed.
  9. Is hemodynamically unstable, including severe heart failure ( Class IV) at Screening.
  10. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to Screening.
  11. Has been randomized into a previous NB (Contrave) study or has been exposed to commercially available NB (Contrave) for any period of time prior to Screening.
  12. Is taking excluded medications within 28 days of Screening.
  13. Has uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mm Hg and/or ≥100 mm Hg diastolic blood pressure (DBP) on the average of two seated blood pressure measurements after being at rest at least 5 minutes, confirmed on 2 separate days during the Screening Period.
  14. Has severe renal impairment defined by estimated (eGFR) \<30 ml/min/1.73 m\^2 based on the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) at Screening.
  15. Has a clinical history of liver failure.
  16. Has a known infection with that is being treated with ritonavir, lopinavir or efavirenz.
  17. Has known acute hepatitis at Screening.
  18. Has chronic use of opioids, defined as longer than 3 months prior to Screening.
  19. Has a positive drug screen for cocaine, methamphetamine, methadone, opiates, oxycodone, phencyclidine, and propoxyphene at Screening. A positive screen for amphetamines, barbiturates, benzodiazepines, and cannabinoids is exclusionary if abuse or dependence is suspected.
  20. Has a history of seizures (including febrile seizures), cranial trauma, or other conditions that predispose the participant to seizures.
  21. Has a history of mania, history of or current diagnosis of bipolar disorder or current diagnosis of active psychosis, active bulimia or anorexia nervosa (binge eating disorder is not exclusionary).
  22. Is at risk for suicide attempts based on the judgment of the investigator.
  23. If female, the participant is pregnant (confirmed by laboratory testing at screening) or lactating or intending to become pregnant from signing the through 12 weeks after last dose of study medication; or intending to donate ova during such time period.
  24. Has a history of severe ischemic stroke (with a Modified Rankin Scale Score ≥4).
  25. Has any major illness or condition that, in the investigator's opinion, prohibits the participant from participating in the study or meeting the planned visit schedule.
  26. Is unable to understand verbal or written English or any other language, for which a certified translation of the approved informed consent is available.

Additional exclusion criteria to be assessed at Visit3 prior to Randomization:

  1. Participant takes \<75% or >125% of the Lead-in study medication.
  2. Participant discontinues study medication treatment or has a known major adverse cardiovascular events (MACE) reported by investigator during the Double-Blind Lead-in Period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Other
    Lead-In: Naltrexone/Bupropion + Placebo

    Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.

    Drug: Naltrexone HCl/Bupropion HCl ER · Drug: Placebo

  • Other
    Lead-In: Placebo + Naltrexone/Bupropion

    Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.

    Drug: Naltrexone HCl/Bupropion HCl ER · Drug: Placebo

  • Active comparator
    Naltrexone/Bupropion

    Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.

    Drug: Naltrexone HCl/Bupropion HCl ER

  • Placebo comparator
    Placebo

    Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.

    Drug: Placebo

Interventions

  • DrugNaltrexone HCl/Bupropion HCl ER

    Drug pages: Naltrexone · Bupropion

    Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets

    Also known as: Contrave

  • DrugPlacebo

    Naltrexone HCl/bupropion HCl placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Time From Treatment Period Randomization to the First Confirmed Occurrence of Major Adverse Cardiovascular Events (MACE)

    MACE are defined as cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.

    Time frame: Day 1 to first confirmed occurrence of MACE (up to 6 years)

Secondary outcomes

  1. Time From Treatment Period Randomization to the First Confirmed Occurrence of Extended Major Adverse Cardiovascular Events (MACE)

    Extended MACE defined as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and unstable angina requiring hospitalization.

    Time frame: Day 1 to first confirmed occurrence of extended MACE (up to 6 years)

  2. Time From Treatment Period Randomization to the Occurrence of All-Cause Death

    Time frame: Day 1 to the occurrence of all-cause death (up to 6 years)

  3. Time From Treatment Period Randomization to the Occurrence of Cardiovascular Death

    Time frame: Day 1 to the occurrence of cardiovascular death (up to 6 years)

07

Results

Posted Feb 27, 2017
Limitations and caveats
As this study was prematurely terminated, analysis of the primary and secondary outcome measures was not performed and analysis of safety was limited in scope.

Participant flow

Participant flow — Overall Study
MilestoneNaltrexone/BupropionPlacebo
Started2830
Completed00
Not completed2830
Withdrew: Study terminated2830

Outcome measures

PrimaryTime From Treatment Period Randomization to the First Confirmed Occurrence of Major Adverse Cardiovascular Events (MACE)

MACE are defined as cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.

Time frame:
Day 1 to first confirmed occurrence of MACE (up to 6 years)

No measurements were reported for this outcome.

SecondaryTime From Treatment Period Randomization to the First Confirmed Occurrence of Extended Major Adverse Cardiovascular Events (MACE)

Extended MACE defined as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and unstable angina requiring hospitalization.

Time frame:
Day 1 to first confirmed occurrence of extended MACE (up to 6 years)

No measurements were reported for this outcome.

SecondaryTime From Treatment Period Randomization to the Occurrence of All-Cause Death
Time frame:
Day 1 to the occurrence of all-cause death (up to 6 years)

No measurements were reported for this outcome.

SecondaryTime From Treatment Period Randomization to the Occurrence of Cardiovascular Death
Time frame:
Day 1 to the occurrence of cardiovascular death (up to 6 years)

No measurements were reported for this outcome.

Adverse events

Collected over Study was terminated with the maximum subject duration on study of 13.1 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naltrexone/Bupropion—2/28 (7.1%)1/28 (3.6%)
Placebo—2/30 (6.7%)2/30 (6.7%)
Most frequent serious events
Most frequent serious events
EventNaltrexone/BupropionPlacebo
Cerebrovascular accidentNervous system disorders1/280/30
Brain stem strokeNervous system disorders1/280/30
VertigoEar and labyrinth disorders0/281/30
ThrombosisVascular disorders0/281/30
Non-cardiac chest painGeneral disorders0/281/30
Most frequent other events
Most frequent other events
EventNaltrexone/BupropionPlacebo
Faeces discolouredGastrointestinal disorders1/280/30
DiarrhoeaGastrointestinal disorders0/281/30
FatigueGeneral disorders0/281/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Naltrexone/BupropionPlaceboTotal
<=18 years000
Between 18 and 65 years191433
>=65 years91625
Age, Continuous
Age, Continuous(years)Naltrexone/BupropionPlaceboTotal
Mean61.3 ± 9.2965.5 ± 7.0463.5 ± 8.40
Sex: Female, Male
Sex: Female, Male(Participants)Naltrexone/BupropionPlaceboTotal
Female6915
Male222143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Naltrexone/BupropionPlaceboTotal
Hispanic or Latino224
Not Hispanic or Latino262854
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Naltrexone/BupropionPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American7714
White192342
More than one race000
Unknown or Not Reported000
08

Study locations

139 sites
  • Alexander City, Alabama, United States
  • Auburn, Alabama, United States
  • Birmingham, Alabama, United States
  • Huntsville, Alabama, United States
  • Campe Verde, Arizona, United States
  • Chandler, Arizona, United States
  • Cottonwood, Arizona, United States
  • Fountain Hills, Arizona, United States
  • Mesa, Arizona, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Fayetteville, Arkansas, United States
  • Jonesboro, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Arvin, California, United States
  • Bakersfield, California, United States
  • Chino, California, United States
  • Downey, California, United States
  • El Cajon, California, United States
  • Los Alamitos, California, United States
  • Los Angeles, California, United States
  • Pamona, California, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Santa Monica, California, United States
  • Denver, Colorado, United States
  • New London, Connecticut, United States
  • Stamford, Connecticut, United States
  • Trumbull, Connecticut, United States
  • Waterbury, Connecticut, United States
  • Wilmington, Delaware, United States
  • Boca Raton, Florida, United States
  • Bradenton, Florida, United States
  • Brandon, Florida, United States
  • Brooksville, Florida, United States
  • Coral Springs, Florida, United States
  • Cutler Bay, Florida, United States
  • Daytona Beach, Florida, United States
  • Hialeah, Florida, United States
  • Inverness, Florida, United States
  • Jacksonville Beach, Florida, United States
  • Lake Worth, Florida, United States
  • Largo, Florida, United States
  • Miami Lakes, Florida, United States
  • Orlando, Florida, United States
  • Palm Harbor, Florida, United States
  • Pembroke Pines, Florida, United States
  • Ponte Vedra Beach, Florida, United States
  • Sarasota, Florida, United States
  • Stuart, Florida, United States
  • Atlanta, Georgia, United States
  • Duluth, Georgia, United States
  • Savannah, Georgia, United States
  • Honolulu, Hawaii, United States
  • Pocatello, Idaho, United States
  • Blue Island, Illinois, United States
  • Chicago, Illinois, United States
  • Evanston, Illinois, United States
  • Gurnee, Illinois, United States
  • Rock Island, Illinois, United States
  • Evansville, Indiana, United States
  • Topeka, Kansas, United States
  • Louisville, Kentucky, United States
  • Owensboro, Kentucky, United States
  • Baton Rouge, Louisiana, United States
  • Bossier City, Louisiana, United States
  • Lake Charles, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Baltimore, Maryland, United States
  • Catonsville, Maryland, United States
  • Bay City, Michigan, United States
  • Saginaw, Michigan, United States
  • Port Gibson, Mississippi, United States
  • Hazelwood, Missouri, United States
  • Great Falls, Montana, United States
  • Las Vegas, Nevada, United States
  • Linden, New Jersey, United States
  • Moorestown, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Endwell, New York, United States
  • Great Neck, New York, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Saratoga Springs, New York, United States
  • Staten Island, New York, United States
  • Asheville, North Carolina, United States
  • Cary, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Durham, North Carolina, United States
  • Greenville, North Carolina, United States
  • Hickory, North Carolina, United States
  • Morehead City, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Rocky Mount, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Winston Salem, North Carolina, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States

Showing the first 100 of 139 sites. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2015
First posted
Dec 22, 2015
Start
Jan 2016
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Results first posted
Feb 27, 2017
Last update
Feb 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02638129
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Dec 22, 2015
Start date
Jan 2016
Primary completion
Jun 2016
Completion
Jun 2016
Results posted
Feb 27, 2017
Last update
Feb 27, 2017

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Bupropion

Start the discussion